Cardiff Oncology to Present at the H.C. Wainwright BioConnect Virtual Conference

Rhea-AI Summary

Cardiff Oncology (Nasdaq: CRDF) announced its participation at the H.C. Wainwright BioConnect Virtual Conference from January 10 to 13, 2022. The presentation will be available on-demand starting at 7:00 AM ET on January 10. Cardiff Oncology focuses on developing precision medicine for cancer patients, specifically targeting KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Their investigational drug, onvansertib, is a third-generation Polo-like Kinase 1 inhibitor designed to improve treatment responses and overall survival.

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer, today announced that company management will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 10 – 13, 2022.

Details on the presentation can be found below.

H.C. Wainwright BioConnect Virtual Conference
Presentation Date:	Available on-demand beginning at 7:00 AM ET on Monday, January 10, 2022

A webcast of the presentation will be available on the "Events" section of the Cardiff Oncology website.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations that overcome disease resistance and improve disease response to standard treatment regimens and to increase overall survival. We are developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 ("PLK1") inhibitor, in combination with standard-of-care anti-cancer therapeutics. Our clinical development programs incorporate tumor genomics and biomarker technology to refine assessment of patient response to treatment. We have three clinical programs currently ongoing: a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin^® (bevacizumab) in KRAS-mutated metastatic colorectal cancer (mCRC); a Phase 2 trial of onvansertib in combination with nanoliposomal irinotecan, leucovorin and fluorouracil for the second-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDAC); and a Phase 2 study of onvansertib in combination with Zytiga^® (abiraterone)/prednisone in metastatic castrate-resistant prostate cancer (mCRPC). For more information, please visit https://www.cardiffoncology.com.  

Cardiff Oncology Contact:
Vicki Kelemen
Chief Operating Officer
858-952-7652 
vkelemen@cardiffoncology.com 

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569 
jallaire@lifesciadvisors.com 

Media Contact:
Amy Jobe, Ph.D.
LifeSci Communications
315-879-8192 
ajobe@lifescicomms.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301453253.html

SOURCE Cardiff Oncology, Inc.

FAQ

When will Cardiff Oncology present at the H.C. Wainwright BioConnect Virtual Conference?

Cardiff Oncology will present at the conference from January 10 to 13, 2022, with the presentation available on-demand starting at 7:00 AM ET on January 10.

What is the focus of Cardiff Oncology's research?

Cardiff Oncology focuses on developing precision medicine treatment options for cancer, particularly for KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer.

What is onvansertib and its significance?

Onvansertib is a first-in-class, third-generation Polo-like Kinase 1 inhibitor being developed by Cardiff Oncology, aimed at improving treatment responses in cancer patients.

How does Cardiff Oncology evaluate treatment responses?

Cardiff Oncology uses tumor genomics and biomarker technology to refine the assessment of patient responses to their cancer treatments.

What are Cardiff Oncology's ongoing clinical programs?

Cardiff Oncology has three ongoing clinical programs evaluating onvansertib combined with standard therapies for KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer.